Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01494233 | A Multi-Center Trial to Determine the Safety and Efficacy of LX1033 in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome | PHASE2 | COMPLETED | 373 | — | — | Feb 1, 2012 | - | Mar 23, 2015 | 81 | United States |
| Arm | Type | Description |
|---|---|---|
| Low dose | EXPERIMENTAL | 500 mg LX1033 two times daily |
| Mid dose | EXPERIMENTAL | 500 mg LX1033 three times daily |
| High dose | EXPERIMENTAL | 1000 mg LX1033 two times daily |
| Placebo | PLACEBO_COMPARATOR | Matching placebo dosing |
| Name | Type | Description |
|---|---|---|
| 250 mg LX1033 tablets | DRUG | 250 mg LX1033 tablets administered orally |
| Placebo tablet | DRUG | Matching placebo tablet administered orally |
Inclusion Criteria: * Male and female subjects, aged 18 to 70 years, with diarrhea-predominant IBS (IBS-D) with symptom onset at least 6 months prior to diagnosis * Two or more days per week with at least one stool with a consistency of Type 6 or 7 (Bristol Stool Form Scale) * Weekly average of wor...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Ardelyx, Inc. | ARDX | 4 | PHASE3 | Tenapanor |
| AbbVie, Inc. | ABBV | 2 | PHASE3 | Eluxadoline |
| Disc Medicine, Inc. | IRON | 1 | PHASE2 | DISC-0974 |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 2 | — | Undisclosed |
| Johnson & Johnson | JNJ | 1 | — | Anti TNF therapy including infliximab, No Biologics |
| Cooper Companies, Inc. | COO | 1 | NA | Undisclosed |